<del id="tdllb"><th id="tdllb"><ins id="tdllb"></ins></th></del>
<strike id="tdllb"></strike><strike id="tdllb"><dl id="tdllb"></dl></strike>
<span id="tdllb"></span>
<span id="tdllb"><video id="tdllb"><ruby id="tdllb"></ruby></video></span><span id="tdllb"></span>
<strike id="tdllb"><dl id="tdllb"></dl></strike>
<strike id="tdllb"><dl id="tdllb"></dl></strike><span id="tdllb"><dl id="tdllb"></dl></span>
<strike id="tdllb"><dl id="tdllb"><del id="tdllb"></del></dl></strike>
<span id="tdllb"><dl id="tdllb"><ruby id="tdllb"></ruby></dl></span> <span id="tdllb"></span>
<strike id="tdllb"><i id="tdllb"><cite id="tdllb"></cite></i></strike><strike id="tdllb"><dl id="tdllb"></dl></strike><strike id="tdllb"><dl id="tdllb"></dl></strike>

Our COVID-19 Rapid
Response Program

Regeneron is applying our 30 years of scientific and technology expertise to combat the COVID-19 pandemic. We feel uniquely positioned to meet this public health threat using our proprietary VelociSuite® technologies and our track record for rapid response against infectious diseases, such as Ebola.

Developing REGN-COV2

A Novel Anti-Viral Antibody Cocktail

We are using our end-to-end antibody technologies to develop REGN-COV2, our novel anti-viral antibody cocktail that is being studied for its potential both to treat people with COVID-19 and to prevent SARS-CoV-2 infection.

REGN-COV2 is currently being studied in four late-stage clinical trials: two Phase 2/3 trials for the treatment of hospitalized and non-hospitalized (“ambulatory”) COVID-19 patients, the open-label, Phase 3 RECOVERY trial of hospitalized COVID-19 patients in the UK, and a Phase 3 trial for the prevention of COVID-19 in uninfected people who are at high-risk of exposure to a COVID-19 patient (such as the patient’s housemate). The Phase 3 prevention trial is being jointly conducted with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The safety of REGN-COV2 is also being evaluated in a Phase 1 healthy volunteer study.

Our COVID-19-related discovery efforts started in early 2020, when we produced hundreds of virus-neutralizing antibodies in our genetically-engineered mice and identified similarly-performing antibodies from human COVID-19 survivors. In April, we moved the two most potent antibodies into cell production lines, in preparation for clinical study and large-scale availability, and clinical trials began in June.

Read more about the clinical program here

We are actively working to maximize production capacity of REGN-COV2 and ensure it reaches as many people as possible in the United States and around the world, should ongoing clinical trials be successful and regulatory approvals are granted.

We are collaborating with Roche to significantly increase the global supply of REGN-COV2, with both companies dedicating a certain manufacturing capacity to REGN-COV2 each year. This is expected to increase existing capacity by at least three and a half times, with the potential for even further expansion. If approved, Regeneron will distribute REGN-COV2 in the U.S. and Roche will be responsible for distribution outside the U.S.

We are also manufacturing and providing REGN-COV2 to the Biomedical Advanced Research and Development Authority (BARDA) and the U.S. Department of Defense. Read more about our manufacturing and supply agreements HERE and HERE.

Two manuscripts published in Science detail the discovery of REGN-COV2 and highlight its potential to protect against ‘viral escape’ of SARS-CoV-2. Viral escape was seen to occur in the setting of a single therapeutic antibody that blocks the ability of a virus to infect healthy cells, and spontaneously arising mutant forms of the virus might ‘escape’ or evade the antibody’s blocking action. These mutants are then ‘selected’ (i.e., are able to survive and proliferate despite the single antibody treatment) and may ultimately become the dominant strain of the virus. The findings show our antibody cocktail may be able to diminish risk of viral escape by binding to the virus’s spike protein in separate, non-overlapping locations, requiring the virus to mutate simultaneously in multiple genetic locations.

Read about our Science publications here

Recent preclinical data demonstrates the efficacy of REGN-COV2 in non-human primates and hamsters, showing its ability to reduce virus load in lower and upper airways and decrease virus-induced pathological impact when administered prophylactically or therapeutically.

Results from investigating one of our existing medicines for COVID-19

Based on early clinical data from China with another IL-6 inhibitor, Regeneron and Sanofi began to evaluate if there was a potential role for Kevzara??(sarilumab) in the treatment of hospitalized patients with COVID-19 by conducting controlled clinical trials.? The use of Kevzara to treat people with COVID-19 is investigational and has not been fully evaluated by any regulatory authority.

Regeneron and Sanofi have announced that the U.S. Phase 2/3 and global Phase 3 clinical trials of Kevzara did not meet their primary or secondary endpoints in COVID-19 patients. Based on the results, the trials were stopped, and at this time, the companies do not anticipate conducting further clinical studies for Kevzara in COVID-19.

Click here for more information

Achieving Immunity to SARS-COV-2:

Get an overview of how anti-viral antibody medicines and vaccines are similar and different.

Download this pdf

Our technologies

From discovery to large-scale manufacturing, our VelociSuite? technologies provide unmatched precision and speed in developing targeted antibody medicines.

Learn about our technologies

COVID-19 Business Updates

Operations:

Given the ongoing nature of this pandemic, we are regularly assessing any potential impact to our business, including aspects of product supply, clinical development and commercial operations. We will share material updates as warranted.

Our team:

Our first priority is to protect the health and safety of our colleagues and ensure the continuity of our business. We are monitoring the pandemic situation closely and have established a senior response committee to assess our guidance continually. Currently, many of our colleagues are working from home if their job allows it. We have taken additional health and safety precautions to protect our critical laboratory and manufacturing colleagues whose jobs require they be on site. These include alternating shift schedules to reduce density on site, a mask requirement on campus, provision of masks and other personal protective equipment, health monitoring for on site colleagues, and physical modifications to office and lab spaces. We are also providing regular on site testing for all colleagues working at our Tarrytown campus.

Clinical trials:

Regeneron conducts clinical trials in multiple countries across the world. We continue to evaluate the impact of the COVID-19 pandemic on an individual clinical trial basis and expect fully-recruited clinical studies to remain generally on track. After briefly pausing new enrollment in certain studies due to the pandemic, enrollment in both new and ongoing clinical studies started to resume as regions relaxed their restrictions and healthcare resources started to become more available for non-COVID-19 activities. However, there has been a resurgence of COVID-19 cases in many regions across the world, and any resurgence in the regions where we or our collaborators conduct clinical trials may require timeline adjustments for potentially impacted studies. We continue to work closely with regulators to follow recent Health Authority and Regulatory Agency issued guidances as they pertain to clinical trial operations.

Supply chain & market supply:

As a matter of practice, we are always working to ensure the stability of our supply chain and maintain adequate market supply for all commercialized products. We maintain adequate market supply for all our commercialized products, and our raw material supplies and contract manufacturing support have remained stable despite the current pandemic situation. In order to enable the U.S. manufacturing site to produce large-scale quantities of REGN-COV2, we have worked with regulatory authorities to accelerate licensing of additional commercial products to be manufactured at our Ireland facility.

Supporting our communities:

Regeneron’s community response focuses on raising critical funds, mobilizing resources and supporting the most vulnerable nonprofits, people and communities around the world. Through Regeneron’s COVID-19 Double Matching Gift Campaign, we are supporting our employees’ giving and select charities with the goal of raising $750,000.

Locally, we are supporting Afya Foundation’s efforts to deliver critically needed medical supplies to qualified, New York-based health centers. In Rensselaer, we are supporting the Capital Region Community Foundation’s COVID-19 Response Fund, which provides flexible resources for nonprofits working with those who are disproportionately impacted. We are planning additional and expanded efforts to support people in need during this critical time and will share more details in this space.

Regeneron’s Industrial Operations and Product Supply (IOPS) team is assisting New York State by making and donating viral transport media (VTM), a critical component of COVID-19 testing kits that has been in short supply. VTM is a liquid used to preserve patient test samples (a swab from the nose or throat) until they can be tested. Regeneron worked to obtain the necessary components, determined formulas and proportions to meet NYS-specifications, and leveraged the specialized skill set of our employees to make sterile VTM and place it into test tubes. We are delivering over 500,000 total VTM kits to New York State and are donating 100 percent of our supplies and labor for this effort, an approximately $1 million in-kind contribution. Learn more.

黄色网站在线观看